Status:
UNKNOWN
Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma
Lead Sponsor:
All India Institute of Medical Sciences
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
12-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Background Hepatocellular carcinoma, a malignant tumour of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives ab...
Detailed Description
Aim The aim of the study is to compare the effect of Oral chemotherapeutic drugs (Thalidomide and Capecitabine) in comparison with supportive therapy in the treatment of advanced Hepatocellular carcin...
Eligibility Criteria
Inclusion
- Patients above 12 years of age with
- ECOG performance status (PST) score of 3 or above
- Underlying Child's A and B cirrhosis
- More than 50% involvement of liver by tumor
- Thrombosed main portal vein
- HV/IVC thrombosis
- Extra hepatic disease
- Metastatic disease
- Informed written consent of patient
Exclusion
- History of drug allergy
- Co-morbid illness like coronary artery disease, congestive heart failure, chronic renal failure etc
- Pregnancy
- Outstation patients from distant areas not in a position to follow up
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2014
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT01438450
Start Date
October 1 2007
End Date
September 1 2014
Last Update
July 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, India, 110029